Invention Publication
- Patent Title: LENTIVIRUS PROTECTION VIA Fc OVEREXPRESSION
-
Application No.: US18279199Application Date: 2022-03-07
-
Publication No.: US20240139341A1Publication Date: 2024-05-02
- Inventor: Tobias Deuse
- Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- Applicant Address: US CA Oakland
- Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- Current Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- Current Assignee Address: US CA Oakland
- International Application: PCT/US2022/019203 2022.03.07
- Date entered country: 2023-08-28
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/86
Abstract:
The invention relates to gene therapies using viral vectors. The invention provides, for the first time, packaging cells that comprise enhanced Fc receptor expression (e.g. CD16, CD32, or CD64) to generate gene therapy viruses that evade antibody-dependent inactivation (ADI) or complement-dependent inactivation (CDI). The invention also provides gene therapy viruses with the enhanced Fc receptors displayed on their viral envelope.
Information query
